Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses the anemia benefit observed with the use of momelotinib in patients with myelofibrosis (MF). Using data from the SIMPLIFY-1 (NCT01969838) and SIMPLIFY-2 (NCT02101268) trials, Dr Mesa explains that patients treated with momelotinib spend less time in a transfusion dependent state than those treated with best available therapy (BAT) or ruxolitinib, highlighting the benefit of this agent. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть